Israel Englander Allogene Therapeutics, Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 256,849 shares of ALLO stock, worth $272,259. This represents 0.0% of its overall portfolio holdings.

Number of Shares

256,849

Holding current value

$272,259

% of portfolio

0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.4 - $2.84 $359,588 - $729,451	256,849 New	256,849 $374,000
Q3 2024 Nov 14, 2024	BUY	$2.08 - $3.5 $163,026 - $274,323	78,378 Added 43.63%	258,002 $722,000
Q2 2024 Aug 14, 2024	SELL	$2.23 - $4.38 $48,716 - $95,685	-21,846 Reduced 10.84%	179,624 $418,000
Q1 2024 May 15, 2024	SELL	$2.92 - $5.63 $5.02 Million - $9.67 Million	-1,717,544 Reduced 89.5%	201,470 $900,000
Q4 2023 Feb 14, 2024	BUY	$2.28 - $3.5 $3.9 Million - $5.98 Million	1,709,248 Added 814.84%	1,919,014 $6.16 Million
Q2 2023 Aug 14, 2023	SELL	$4.53 - $6.74 $3.59 Million - $5.35 Million	-793,230 Reduced 79.09%	209,766 $1.04 Million
Q1 2023 May 15, 2023	SELL	$4.92 - $8.21 $11.2 Million - $18.7 Million	-2,272,128 Reduced 69.38%	1,002,996 $4.96 Million
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $10.6 Million - $20.9 Million	1,878,645 Added 134.53%	3,275,124 $20.6 Million
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $6.39 Million - $10.7 Million	619,607 Added 79.76%	1,396,479 $15.1 Million
Q2 2022 Aug 15, 2022	BUY	$6.78 - $12.28 $1.39 Million - $2.53 Million	205,666 Added 36.01%	776,872 $8.86 Million
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $3.18 Million - $6.36 Million	416,173 Added 268.44%	571,206 $5.2 Million
Q4 2021 Feb 14, 2022	SELL	$13.13 - $24.52 $966,236 - $1.8 Million	-73,590 Reduced 32.19%	155,033 $2.31 Million
Q3 2021 Nov 15, 2021	SELL	$21.01 - $27.64 $5.81 Million - $7.65 Million	-276,672 Reduced 54.75%	228,623 $5.88 Million
Q2 2021 Aug 16, 2021	BUY	$23.49 - $35.8 $5.22 Million - $7.96 Million	222,330 Added 78.57%	505,295 $13.2 Million
Q1 2021 May 17, 2021	SELL	$25.79 - $39.02 $3.68 Million - $5.56 Million	-142,517 Reduced 33.5%	282,965 $9.99 Million
Q4 2020 Feb 16, 2021	BUY	$25.24 - $43.45 $9.02 Million - $15.5 Million	357,234 Added 523.44%	425,482 $10.7 Million
Q3 2020 Nov 16, 2020	SELL	$32.38 - $44.96 $4.5 Million - $6.25 Million	-138,931 Reduced 67.06%	68,248 $2.57 Million
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $2.86 Million - $8.41 Million	155,678 Added 302.28%	207,179 $8.87 Million
Q1 2020 May 14, 2020	SELL	$18.22 - $28.25 $371,542 - $576,074	-20,392 Reduced 28.36%	51,501 $1 Million
Q4 2019 Feb 14, 2020	BUY	$24.82 - $31.4 $1.78 Million - $2.26 Million	71,893 New	71,893 $1.87 Million

Others Institutions Holding ALLO

# of Institutions

176

Shares Held

165M

Call Options Held

202K

Put Options Held

76.6K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $152M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account